FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318577146> ?p ?o ?g. }

• W4318577146 endingPage "i637" @default.
• W4318577146 startingPage "i636" @default.
• W4318577146 abstract "Abstract Background Upadacitinib (UPA) is an oral selective Janus kinase inhibitor with demonstrated efficacy in induction and maintenance treatment of Crohn’s disease (CD). This post hoc analysis assessed the efficacy of UPA in patients with CD by baseline (BL) disease severity. Methods In the U-EXCEL (NCT03345849) and U-EXCEED (NCT03345836) induction studies, patients with moderate-to-severe CD and intolerance/inadequate response to biologic therapy (both studies) and/or conventional therapy (U-EXCEL) received UPA 45 mg once daily (QD) or placebo (PBO) for 12 weeks. Patients who achieved clinical response to UPA induction were re-randomised in a maintenance study (U-ENDURE, NCT03345823) to receive UPA 15 mg QD, UPA 30 mg QD, or PBO for 52 weeks. Clinical remission and endoscopic response were evaluated in subgroups stratified by BL disease characteristics: Crohn’s Disease Activity Index (CDAI), very soft/liquid stool frequency (SF), abdominal pain score (APS), and Simple Endoscopic Score for CD (SES-CD). Patients from the U-EXCEL and U-EXCEED studies were pooled for analysis. Results Among 1021 patients with moderate-to-severe CD (UPA 45 mg, n=674; PBO, n=347), week 12 clinical remission and endoscopic response rates were significantly higher for patients receiving UPA 45 mg vs PBO regardless of BL disease severity (nominal P &lt;.01), except SES-CD &lt;6 (UPA, n=35; all had ileal disease only per the inclusion criteria) (Figure 1). UPA efficacy rates were higher compared with PBO across BL CDAI, with variable treatment effects. Patients with lower BL SF achieved clinical remission and endoscopic response with UPA 30 mg at higher rates than those with higher BL SF at week 12 and week 52. At week 12, the absolute efficacy rates and treatment differences for clinical remission and endoscopic response were generally similar across BL APS. Patients with higher BL SES-CD (≥15) generally achieved higher rates of clinical remission and endoscopic response at week 12 with UPA vs PBO than those with lower BL SES-CD (6–14). At week 52, clinical remission and endoscopic response rates were generally higher for patients receiving UPA vs PBO and most were consistent with a dose-response relationship (Figure 2). Generally, larger treatment differences between UPA and PBO were observed for patients with the most severe disease per SES-CD. Conclusion UPA induction and maintenance therapy improved clinical and endoscopic outcomes vs PBO in patients with moderate-to-severe CD, across levels of disease severity. Data for the small subgroup of patients with SES-CD &lt;6 should be interpreted cautiously given lower mucosal healing rates in isolated ileal CD.1 Reference: 1. Atreya R, et al.Curr Res Pharmacol Drug Discov. 2022;3:100097." @default.
• W4318577146 created "2023-01-31" @default.
• W4318577146 creator A5001142571 @default.
• W4318577146 creator A5005601386 @default.
• W4318577146 creator A5005710404 @default.
• W4318577146 creator A5014880755 @default.
• W4318577146 creator A5037680180 @default.
• W4318577146 creator A5040354010 @default.
• W4318577146 creator A5040820024 @default.
• W4318577146 creator A5046586589 @default.
• W4318577146 creator A5061669463 @default.
• W4318577146 creator A5083074756 @default.
• W4318577146 creator A5088717074 @default.
• W4318577146 creator A5089666701 @default.
• W4318577146 date "2023-01-30" @default.
• W4318577146 modified "2023-10-08" @default.
• W4318577146 title "P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity" @default.
• W4318577146 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0636" @default.
• W4318577146 hasPublicationYear "2023" @default.
• W4318577146 type Work @default.
• W4318577146 citedByCount "0" @default.
• W4318577146 crossrefType "journal-article" @default.
• W4318577146 hasAuthorship W4318577146A5001142571 @default.
• W4318577146 hasAuthorship W4318577146A5005601386 @default.
• W4318577146 hasAuthorship W4318577146A5005710404 @default.
• W4318577146 hasAuthorship W4318577146A5014880755 @default.
• W4318577146 hasAuthorship W4318577146A5037680180 @default.
• W4318577146 hasAuthorship W4318577146A5040354010 @default.
• W4318577146 hasAuthorship W4318577146A5040820024 @default.
• W4318577146 hasAuthorship W4318577146A5046586589 @default.
• W4318577146 hasAuthorship W4318577146A5061669463 @default.
• W4318577146 hasAuthorship W4318577146A5083074756 @default.
• W4318577146 hasAuthorship W4318577146A5088717074 @default.
• W4318577146 hasAuthorship W4318577146A5089666701 @default.
• W4318577146 hasBestOaLocation W43185771461 @default.
• W4318577146 hasConcept C121608353 @default.
• W4318577146 hasConcept C126322002 @default.
• W4318577146 hasConcept C141071460 @default.
• W4318577146 hasConcept C142724271 @default.
• W4318577146 hasConcept C204787440 @default.
• W4318577146 hasConcept C27081682 @default.
• W4318577146 hasConcept C2778435480 @default.
• W4318577146 hasConcept C2779134260 @default.
• W4318577146 hasConcept C2779280984 @default.
• W4318577146 hasConcept C2780955771 @default.
• W4318577146 hasConcept C526805850 @default.
• W4318577146 hasConcept C535046627 @default.
• W4318577146 hasConcept C67761136 @default.
• W4318577146 hasConcept C71924100 @default.
• W4318577146 hasConcept C90924648 @default.
• W4318577146 hasConceptScore W4318577146C121608353 @default.
• W4318577146 hasConceptScore W4318577146C126322002 @default.
• W4318577146 hasConceptScore W4318577146C141071460 @default.
• W4318577146 hasConceptScore W4318577146C142724271 @default.
• W4318577146 hasConceptScore W4318577146C204787440 @default.
• W4318577146 hasConceptScore W4318577146C27081682 @default.
• W4318577146 hasConceptScore W4318577146C2778435480 @default.
• W4318577146 hasConceptScore W4318577146C2779134260 @default.
• W4318577146 hasConceptScore W4318577146C2779280984 @default.
• W4318577146 hasConceptScore W4318577146C2780955771 @default.
• W4318577146 hasConceptScore W4318577146C526805850 @default.
• W4318577146 hasConceptScore W4318577146C535046627 @default.
• W4318577146 hasConceptScore W4318577146C67761136 @default.
• W4318577146 hasConceptScore W4318577146C71924100 @default.
• W4318577146 hasConceptScore W4318577146C90924648 @default.
• W4318577146 hasIssue "Supplement_1" @default.
• W4318577146 hasLocation W43185771461 @default.
• W4318577146 hasOpenAccess W4318577146 @default.
• W4318577146 hasPrimaryLocation W43185771461 @default.
• W4318577146 hasRelatedWork W1997244387 @default.
• W4318577146 hasRelatedWork W2106112895 @default.
• W4318577146 hasRelatedWork W2170272972 @default.
• W4318577146 hasRelatedWork W2425239049 @default.
• W4318577146 hasRelatedWork W2911805811 @default.
• W4318577146 hasRelatedWork W2979752917 @default.
• W4318577146 hasRelatedWork W2992015492 @default.
• W4318577146 hasRelatedWork W3081516035 @default.
• W4318577146 hasRelatedWork W3200758576 @default.
• W4318577146 hasRelatedWork W4316078287 @default.
• W4318577146 hasVolume "17" @default.
• W4318577146 isParatext "false" @default.
• W4318577146 isRetracted "false" @default.
• W4318577146 workType "article" @default.